Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Sponsor
Bristol-Myers Squibb
Study ID
NCT07557498
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

Key Dates

First listed
Apr 29, 2026
Start date
Jan 15, 2026
Status verified
Apr 2026
Primary completion
Dec 14, 2026
Completion
Jun 17, 2027

Study Design

Enrollment
362 participants (estimated)

Arms

  • Arm: Group 1
    Participants with obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten
  • Arm: Group 2
    Physicians treating patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)

Primary Outcome Measure

Participant blood pressure (both systolic and diastolic) [ Time Frame: Baseline ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.